View Financial HealthCharming Medical 配当と自社株買い配当金 基準チェック /06Charming Medical配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Mar 28Charming Medical Limited Announces Resignation of Independent Director Josephine Yan Yeung, Effective March 27, 2026Charming Medical Limited announced that on March 27, 2026, Ms. Josephine Yan Yeung notified the Company of her resignation as an independent director, effective March 27, 2026, in order to pursue other business commitments. On March 27, 2026, the Board of Directors of the Company accepted and approved Ms. Yeung's resignation. The Company is in the process of identifying a suitable replacement and expects to fill the vacancy by April 2, 2026.お知らせ • Jan 08Charming Medical Limited Announces Board ChangesCharming Medical Limited on December 23, 2025, Mr. Leut Ming Gung notified the Company of his resignation as an independent director, effective December 31, 2025, in order to pursue other business commitments. Mr. Gung’s resignation was not a result of any disagreement with the Company’s operations, policies, or procedures. On January 5, 2026, the Board of Directors of the Company accepted and approved Mr. Gung’s resignation. On January 5, 2026, the Board of Directors, Nominating Committee, and the Compensation Committee approved by resolutions and confirmed the appointment of Mr. Yin Jiang as a director of the Company, with an annual compensation of HKD 240,000, effective upon approval of the resolutions, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined Mr. Jiang is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules. Mr. Jiang will be serving on the Board of Directors as a non-employee, independent director. Mr. Jiang has also been named as the chairman of the Compensation Committee and a member of the Audit Committee and Nominating Committee of the Company. Mr. Jiang has been involved in fund management activities since 2016. In 2017, he founded Panshi Capital, a private equity fund, which was acquired in 2019 by a multi-billion RMB institution in China. He also has experience in artificial intelligence and blockchain technologies and holds multiple invention patents and software copyrights in these fields. In 2013, Mr. Jiang founded Panzhong Technology Co. Ltd., a technology company focused on fiber-optic communication and high-performance computing applications. From 2004 to 2013, he served as a software test engineer at Cisco WebEx. Mr. Jiang received a Bachelor of Science degree in Applied Physics from the University of Science and Technology of China in 2004 and holds a securities investment fund qualification certificate issued by the Asset Management Association of China.お知らせ • Dec 20Robbins LLP Informs Investors of the Charming Medical, Limited Securities Class ActionRobbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited securities between October 10, 2025 and November 12, 2025. The Company claims to "enhance the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology." The Allegations: Robbins LLP is Investigating Allegations that Charming Medical, Limited (MCTA) Engaged in a Fraudulent Stock Promotion Scheme. According to the complaint, defendants failed to disclose that: (1) Charming was the subject of a fraudulent stock promotion scheme involving social media based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) Charming's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price. Plaintiff alleges that in the weeks leading up to November 12, 2025, Charming's share price surged from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news from the Company justifying such a spike. Investigations and public reports have revealed that Charming's stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Charming in online forums, chat groups, and through social media posts with sensational, but baseless, claims to create a buying frenzy among retail investors. On November 12, 2025, the SEC halted trading of Charming's stock. The stock remains halted because the Company has not provided the information regulators required to lift the suspension.Board Change • Oct 22High number of new directorsIndependent Director Josephine Yeung was the last director to join the board, commencing their role in 2025.お知らせ • Oct 21Charming Medical Limited has completed an IPO in the amount of $6.4 million.Charming Medical Limited has completed an IPO in the amount of $6.4 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 Discount Per Security: $0.28決済の安定と成長配当データの取得安定した配当: MCTAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: MCTAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Charming Medical 配当利回り対市場MCTA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (MCTA)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Consumer Services)2.4%アナリスト予想 (MCTA) (最長3年)n/a注目すべき配当: MCTAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: MCTAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: MCTAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: MCTAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/08 03:12終値2025/11/11 00:00収益2025/03/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Charming Medical Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 28Charming Medical Limited Announces Resignation of Independent Director Josephine Yan Yeung, Effective March 27, 2026Charming Medical Limited announced that on March 27, 2026, Ms. Josephine Yan Yeung notified the Company of her resignation as an independent director, effective March 27, 2026, in order to pursue other business commitments. On March 27, 2026, the Board of Directors of the Company accepted and approved Ms. Yeung's resignation. The Company is in the process of identifying a suitable replacement and expects to fill the vacancy by April 2, 2026.
お知らせ • Jan 08Charming Medical Limited Announces Board ChangesCharming Medical Limited on December 23, 2025, Mr. Leut Ming Gung notified the Company of his resignation as an independent director, effective December 31, 2025, in order to pursue other business commitments. Mr. Gung’s resignation was not a result of any disagreement with the Company’s operations, policies, or procedures. On January 5, 2026, the Board of Directors of the Company accepted and approved Mr. Gung’s resignation. On January 5, 2026, the Board of Directors, Nominating Committee, and the Compensation Committee approved by resolutions and confirmed the appointment of Mr. Yin Jiang as a director of the Company, with an annual compensation of HKD 240,000, effective upon approval of the resolutions, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined Mr. Jiang is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules. Mr. Jiang will be serving on the Board of Directors as a non-employee, independent director. Mr. Jiang has also been named as the chairman of the Compensation Committee and a member of the Audit Committee and Nominating Committee of the Company. Mr. Jiang has been involved in fund management activities since 2016. In 2017, he founded Panshi Capital, a private equity fund, which was acquired in 2019 by a multi-billion RMB institution in China. He also has experience in artificial intelligence and blockchain technologies and holds multiple invention patents and software copyrights in these fields. In 2013, Mr. Jiang founded Panzhong Technology Co. Ltd., a technology company focused on fiber-optic communication and high-performance computing applications. From 2004 to 2013, he served as a software test engineer at Cisco WebEx. Mr. Jiang received a Bachelor of Science degree in Applied Physics from the University of Science and Technology of China in 2004 and holds a securities investment fund qualification certificate issued by the Asset Management Association of China.
お知らせ • Dec 20Robbins LLP Informs Investors of the Charming Medical, Limited Securities Class ActionRobbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited securities between October 10, 2025 and November 12, 2025. The Company claims to "enhance the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology." The Allegations: Robbins LLP is Investigating Allegations that Charming Medical, Limited (MCTA) Engaged in a Fraudulent Stock Promotion Scheme. According to the complaint, defendants failed to disclose that: (1) Charming was the subject of a fraudulent stock promotion scheme involving social media based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) Charming's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price. Plaintiff alleges that in the weeks leading up to November 12, 2025, Charming's share price surged from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news from the Company justifying such a spike. Investigations and public reports have revealed that Charming's stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Charming in online forums, chat groups, and through social media posts with sensational, but baseless, claims to create a buying frenzy among retail investors. On November 12, 2025, the SEC halted trading of Charming's stock. The stock remains halted because the Company has not provided the information regulators required to lift the suspension.
Board Change • Oct 22High number of new directorsIndependent Director Josephine Yeung was the last director to join the board, commencing their role in 2025.
お知らせ • Oct 21Charming Medical Limited has completed an IPO in the amount of $6.4 million.Charming Medical Limited has completed an IPO in the amount of $6.4 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 Discount Per Security: $0.28